Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (November 2020)

26 slides from Aerie Pharmaceuticals's investor presentation, Nov 17, 2020

  1. Slide 1: Company Overview Investor Presentation November 2020

    Slide 1: Company Overview Investor Presentation November 2020

    Company Overview Investor Presentation November 2020 Exhibit 99.1

  2. Slide 2: Important Information

    Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    Aerie Overview Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indicat

  4. Slide 4: Aerie's Key Catalysts for 2020

    Slide 4: Aerie's Key Catalysts for 2020

    Aerie’s Key Catalysts for 2020 Pipeline: Successful AR-1105 Phase 2 RVO clinical study topline readout took place in July 2020 Exploring regulatory and commercial pathways for AR-1105 AR-15512 TRPM8 agonist for Dry Eye Phase 2b clinical study commenced in October 2020 Globalization: Roclanda® Mercur

  5. Slide 5: Aerie Overview: U.S. Glaucoma Market

    Slide 5: Aerie Overview: U.S. Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

  6. Slide 6: Glaucoma Commercialization Focus

    Slide 6: Glaucoma Commercialization Focus

    Glaucoma Commercialization Focus Ongoing communication of the MOST Data and coverage via various communication channels Rhopressa® Coverage: 90% Commercial, 89% Med D Rocklatan® Coverage: 89% Commercial, 56% Med D plus 15% Low Income Subsidy Continued execution of the Pulse Strategy, focused on driv

  7. Slide 7: Topline Results from Rhopressa Phase 4 MOST Study

    Slide 7: Topline Results from Rhopressa Phase 4 MOST Study

    Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

  8. Slide 8: U.S. Glaucoma Franchise Launch Update

    Slide 8: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 11/6/2020 IQVIA Weekl

  9. Slide 9: Advancing the Pipeline

    Slide 9: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

  10. Slide 10: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    Slide 10: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health

  11. Slide 11: AR-15512 for Dry Eye: Novel Mechanism of Action

    Slide 11: AR-15512 for Dry Eye: Novel Mechanism of Action

    AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear

  12. Slide 12: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works

    Slide 12: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  13. Slide 13: AR-15512 for Dry Eye Phase 2a study

    Slide 13: AR-15512 for Dry Eye Phase 2a study

    AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t

  14. Slide 14: Significant efficacy achieved for sign and symptoms with BID dosing

    Slide 14: Significant efficacy achieved for sign and symptoms with BID dosing

    Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use ++Data on File Symptoms: SANDE Score Percentage of patients improving ≥20 score p=0.1 p=0.021 Graph on the right represents primary endpoint with a subset of more se

  15. Slide 15: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights: Schirmer

    Slide 15: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights: Schirmer

    ++Data on File For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days

  16. Slide 16: Dry Eye Program: AR-15512

    Slide 16: Dry Eye Program: AR-15512

    For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on

  17. Slide 17: AR-15512 Development Update

    Slide 17: AR-15512 Development Update

    For Investor Use AR-15512 Development Update Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b clinical study commenced October 2020 Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% BID 360 patients (1:1:1) for 3 months Envi

  18. Slide 18: 2019 U.S. Retinal Disease Market

    Slide 18: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

  19. Slide 19: Aerie's Lead Implant Product Candidates

    Slide 19: Aerie's Lead Implant Product Candidates

    For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 Topline reported July 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved

  20. Slide 20: AR-1105: Phase 2 Topline Summary

    Slide 20: AR-1105: Phase 2 Topline Summary

    AR-1105: Phase 2 Topline Summary The Phase 2 clinical trial (AR-1105-CS201) was conducted at 19 centers in the United States. A total of 49 patients completed the study. The objective of the Phase 2 clinical trial was to evaluate two formulations of AR-1105, clinical formulation #1 (CF-1) and clinic

  21. Slide 21: AR-1105: Opportunity Considerations

    Slide 21: AR-1105: Opportunity Considerations

    AR-1105: Opportunity Considerations The Diabetic Macular Edema market is expected to grow with increasing diabetes prevalence in the United States and abroad. The performance of AR-1105 as indicated in the P2 topline data, which reflects six-month sustained delivery, may render this product, if appr

  22. Slide 22: Expanding Aerie Franchise: Japan

    Slide 22: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 Phase 3 trials expected to commence in Japan Q4 2020 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020. *TRx calculated from IQVIA unit data (1 month = 1

  23. Slide 23: Japan Phase 2 Study Topline Results

    Slide 23: Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  24. Slide 24: Japan Phase 2 Study Topline Results: Mean Diurnal IOP

    Slide 24: Japan Phase 2 Study Topline Results: Mean Diurnal IOP

    P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use

  25. Slide 25: Expanding Aerie Franchise: Europe

    Slide 25: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Positive CHMP opinion for Roclanda® (Rocklatan®) received in November 2020, EMA approval expected late 2020 / early 2021 Mercury 3: Reported successful 90-day topline data

  26. Slide 26: Summary Key Priorities

    Slide 26: Summary Key Priorities

    For Investor Use Summary Key Priorities Rhopressa® and Rocklatan® gaining momentum in the United States Globalization Strategy Japan: Santen collaboration commencing Europe: Interest expressed from potential collaborators Ireland Manufacturing Facility approved for U.S. production of Rhopressa® and

Source: SEC EDGAR · 8-K filed Nov 17, 2020

More decks from Aerie Pharmaceuticals Inc.